The Promise of Stabilised CPPs in Intracellular Delivery

Intracellular delivery remains a key challenge for antiviral therapies, as noted in an insightful paper published in the May 2024 issue of the Cellular Signalling research journal (volume 117):

"Instead of putting efforts toward finding new antiviral therapy drugs, it is suggested that the delivery system be optimized. Developing an effective and safe intracellular delivery vehicle (such as CPPs) is crucial for increasing the efficiency of antiviral medications in vivo."

At Sutura Therapeutics, we couldn't agree more! We have developed a new class of stabilised CPPs which have demonstrated enhanced delivery of a variety of macromolecular payloads, with the potential to transform existing therapies, salvage promising failures, or develop novel new gene and protein-targeting treatments.

Read the full article for a comprehensive look at CPP uptake pathways and their implications for drug delivery, gene therapy, and vaccine development: https://www.sciencedirect.com/science/article/abs/pii/S0898656824000846

#CellPenetratingPeptides #AntiviralTherapy #DrugDeliveryOptimisation #IntracellularDelivery